Replimune Group, Inc.’s Registered Equity Offering

Cravath represented the underwriters, led by J.P. Morgan Securities, SVB Leerink and BMO Capital Markets, in connection with the $115 million registered equity offering of Replimune Group, Inc., a biotechnology company developing oncolytic immuno‑gene therapies derived from its Immulytic™ platform. The offering consisted of shares of Replimune’s common stock and pre‑funded warrants to acquire shares of its common stock. The shares were listed on The Nasdaq Global Select Market. The transactions closed on June 11, 2020 and June 29, 2020.

The Cravath team included partner William V. Fogg and associates William F. Roegge, Eric S. Goodwin and Kevin L. Cheng on capital markets matters, partner Christopher K. Fargo and associates Richard M. Bohm and Carlos Nicholas Obando on tax matters, and practice area attorney Anthony N. Magistrale on intellectual property matters.